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http:WHAT THIS PAPER ADDS
This study demonstrates that the expression of the chemokine receptor CXCR4 and its ligand CXCL12 is
signiﬁcantly upregulated in human AAA compared with non-aneurysmal aortic tissue. CXCR4 is mainly co-
localized in inﬂammatory cells, particularly in B and T lymphocytes as well as macrophages. Consequently,
CXCR4 might be involved in inﬂammatory proteolytic processes in the pathogenesis of AAA.Objectives: The aim of the study was to evaluate the potential role of chemokine receptor CXCR4 and its ligand
CXCL12 in the pathogenesis of abdominal aortic aneurysm (AAA).
Methods: AAA tissue specimens were obtained from the anterior or lateral aneurysm sac of patients (n ¼ 32, 26
males, 6 females; 66.8  11.2 years, diameter 64.4  17.0 mm), who underwent elective open surgical repair.
Twelve non-aneurysmal aortic specimens from transplant donors served as controls. Expression analysis of CXCR4
and CXCL12 at mRNA and protein level was determined by quantitative reverse transcriptionepolymerase chain
reaction (RT-PCR) and western blot. Immunohistochemical staining of corresponding histological sections for CD3
(T-cells), CD20 (B-cells), and CD68 (macrophages) was performed to determine the cellular localization of CXCR4
and CXCL12. Data were analyzed with SPSS 20.0 using ManneWhitney U test and Spearman’s rank correlation
coefﬁcient.
Results: Gene expression of CXCR4 and CXCL12 was 9.6 and 4.6 fold higher in AAA than in non-aneurysmal aorta
(p ¼ .0004 and p < .0001, respectively). Likewise, the protein level of CXCR4 was increased 3.2 fold in AAA wall
compared with non-aneurysmal aortic tissue (p < .0001), although CXCL12 could not be detected.
Immunohistochemical analysis revealed that CXCR4 was expressed in B and T lymphocytes and macrophages, and
CXCL12 was observed only in plasma cells.
Conclusions: This study conﬁrmed the over expression of CXCR4 in human AAA tissue. CXCR4 was detected both
at the mRNA and the protein level and by immunohistochemistry, especially in inﬂammatory cells. In contrast,
CXCL12 expression was observed only at the mRNA level, with the exception of plasma cells. The exact role of
CXCR4/CXCL12 in AAA has to be further elucidated.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Abdominal aortic aneurysm (AAA) is a common pathology
of the elderly population,1,2 which may lead to rupture
causing severe internal bleeding and sudden death.3e6 The
pathological dilatation of the aorta is considered to be therresponding author. Department of Vascular and Endovascular
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//dx.doi.org/10.1016/j.ejvs.2015.07.040result of chronic inﬂammation, upregulation of proteolytic
pathways, oxidative stress, degradation of the extracellular
matrix (ECM), and vascular smooth muscle cell (VSMC)
apoptosis.6e11
Inﬂammatory response and activation of proteolytic en-
zymes are widely controlled by a plethora of various che-
mokines and their receptors.12e17 Increased attention has
been paid to one particular chemokine receptor CXCR4,
speciﬁc for stromal derived factor-1 alpha (SDF-1a also
known as CXCL12), involved in the activation and chemo-
tactic attraction of lymphocytes at the site of inﬂammation.
Moreover, CXCR4 and its ligand CXCL12 appear to play a key
role in many immunological areas such as organogenesis,
vascularization, and embryogenesis.18e20 Additionally,
Table 1. Patient demographic data.
Number of patients 32 (26 males, 6
females)
Age (years) (median/range) 68.5/40e87
Max AAA diameter (mm) (median/
range)
59.5/40e90
Number of patients with n/%
Chronic kidney diseasea 12/37.5
Hypertensionb 26/81.3
Diabetes mellitus 1/3.1
Coronary heart diseasec 6/18.8
Positive smoking status 8/25
Medication n/%
ASA 23/71.9
Beta blocker 20/62.5
Statins 18/56.3
746 F. Tanios et al.CXCR4 has already been investigated as a key receptor in
the crosstalk between tumor cells and their microenviron-
ment21,22 and between the immune and the nervous sys-
tems.23,24 The exact role of CXCR4 in human AAA is
however still unknown. Ocaña et al.25 have shown that
CXCR4 was highly expressed in inﬁltrating cells, especially T
and B lymphocytes, isolated from human AAA. Further-
more, the level of CXCL12 was increased in the adventitia of
human AAA wall, presuming an important role of CXCR4/
CXCL12 in the development of AAA.26
The aim of this study was to analyze the expression of
CXCR4 and its ligand CXCL12 in human AAA tissue samples
and compare the results with that of the non-aneurysmal
aorta. Furthermore, the aim was to identify the cellular
localization of CXCR4 and CXCL12 within the aortic wall.ACE inhibitors 13/40.6
Diuretics 13/40.6
ACE ¼ angiotensin converting enzyme ASA ¼ aspirin.
a Estimated glomerular ﬁltration rate <60 mL/min.
b Systolic/diastolic pressure exceeding 140/90 mmHg; six patients
had normal blood pressure, three were without any treatment
regarding antihypertensives, and the other three were treated
with ACE inhibitors.
c All cardiac disorders including stable angina, unstable angina and
myocardial infarction.METHODS
Patients and tissue samples
All AAA tissue samples (n ¼ 32) were obtained, based on
computed tomography (CT) data, from the anterior or
lateral AAA sac at the maximum dilatation area of the AAA
during elective open surgical repair. The AAA tissue samples
were randomly excised from an anterior or lateral aneurysm
sac depending upon the nature of the aneurysm, and on
still being able to fully cover the aortic prosthesis. The
average age of the study patients (26 males, 6 females) was
66.8  11.2 years. The maximum AAA diameter derived
from pre-operative CT-scans was 64.4  17.0 mm. The de-
mographic data of the study patients, including age, sex,
smoking history, comorbidities such as coronary heart dis-
ease (CHD), hypertension, diabetes mellitus (DM), hyper-
lipidemia, medications (aspirin, beta blocker, statins, ACE
(angiotensin converting enzyme) inhibitors, diuretics) ob-
tained from the patient’s medical report, are summarized in
Table 1. Moreover, the glomerular ﬁltration rate (GFR) was
estimated according to clinical guidelines for the diagnosis,
prevention, and treatment of chronic kidney disease
(CKD).27 Study individuals with eGFR < 60 mL/min were
considered as CKD patients. Non-aneurysmal aortic speci-
mens from peri-renal abdominal aorta (n ¼ 12, 10 males, 2
females; 45  17 years), obtained from human organ do-
nors during kidney transplantation at the Department of
Transplant Surgery, Klinikum rechts der Isar, were used as
controls. The aortic tissue samples from AAA patients and
from the healthy donors were obtained from all three vessel
wall layers: adventitia, media, and intima. Following exci-
sion, the tissue specimens were separated into two parts.
One part was ﬁxed in formalin and embedded in parafﬁn
(FFPE), the other part was immediately frozen in liquid ni-
trogen. Fresh frozen samples were used for protein
extraction and western blot analyses; quantitative real time
reverse transcriptaseepolymerase chain reaction (RT-PCR),
histological, and immunohistochemical analyses were per-
formed using FFPE samples.
Informed written consent was obtained from all patients.
The study was performed with the approval of the ethicscommittee of the university hospital Klinikum rechts der
Isar, Technische Universitaet Muenchen, Germany.Chemokine mRNA determination by quantitative real time
RT-PCR
Quantitative real time RT-PCR was performed using FFPE
tissue samples. Total RNA was isolated using High Pure RNA
Parafﬁn Kit (Roche, Mannheim, Germany) and transcribed
into complementary DNA with cDNA Synthesis Kit Revert
Aid (Fermentas, St. Leon-Rot, Germany) according to the
manufacturer’s instructions. SYBR Green ﬂuorescence dye
(peqLab, Erlangen, Germany) and SYBR Green Cycler Ste-
pOnePlus (Life Technologies, Darmstadt, Germany) were
used to quantify PCR results. PCR conditions were as fol-
lows: initial PCR activation step for 5 minutes at 95 C,
followed by 45 thermal cycles of denaturation for 10 sec-
onds at 95 C, annealing temperature for 30 seconds at
60 C, extension for 10 seconds at 72 C, and an additional
15 seconds at 77 C to eliminate primer dimers. The mRNA
levels for each target gene were standardized to the
expression levels of glyceraldehyde-3-phosphate dehydro-
genase (GAPDH). The following commercial available
primers were used: QuantiTect Primer Assay (Qiagen, Hil-
den, Germany): GAPDH (Hs_GAPDH_1_SG, NM_001256799,
95 bp) CXCR4 (Hs_CXCR4_1_SG, NM_001008540, 106 bp),
CXCL12 (SDF-1a) (Hs_CXCL12_1_SG, NM_000609, 70 bp)
CD3 (cluster of differentiation 3; T-cell marker)
(Hs_CD3D_1_SG, NM_000732, 72 bp), MSR1 (macrophage
scavenger receptor 1) (Hs_MSR1_1_SG, NM_002445,
91 bp), and CD45 (cluster of differentiation 45; leucocytes
marker) (Hs_PTPCR_5_SG, NM_002838, 159 bp)
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Tissue samples were homogenized in liquid nitrogen using a
mortar and pestle and suspended in RIPA buffer (50 mm
Tris-HCl [pH 7.5], 150 mm sodium chloride, 1% NP-40, 0.5%
sodium deoxycholate, 0.1% sodium dodecyl sulfate), sup-
plied with freshly prepared protease inhibitor mix (Roche,
Mannheim, Germany) for 30 minutes on ice. Samples were
centrifuged at 14,000  g for 30 minutes at 4 C and the
supernatant containing protein extract was used for further
analysis. The protein concentration was determined using
the BCA Protein Assay Kit (Pierce, Thermo Scientiﬁc, Rock-
ford, IL, USA). Equal amounts of protein from each sample
(50 mg) were fractioned by sodium dodecyl sulfateepoly-
acrylamide gel electrophoresis and transferred onto a pol-
yvinylidene diﬂuoride (PVDF) membrane. The membrane
was blocked for 1 hour with Tris-buffered saline (TBS)
containing 5% (w/v) milk and 0.1% Tween and incubated
with the primary antibody overnight at 4 C. The blots were
washed with TBS containing Tween, incubated with the
appropriate horseradish peroxidase-conjugated secondary
antibodies (R&D Systems Inc., Minneapolis, MN, USA) for
another hour at room temperature. The speciﬁc proteins
were detected by the chemiluminescence reaction (Thermo
Scientiﬁc, Rockford, IL, USA). Protein quantiﬁcation was
performed by comparing the band intensity of each sample
with the intensity of the corresponding GAPDH band. The
following primary antibodies were used: anti-CXCR4 poly-
clonal antibody (ab2074, Abcam Inc., Cambridge, UK; dilu-
tion 1:1,000), anti-SDF-1a (ab9797, Abcam Inc., Cambridge,
UK; dilution 1:1,000), and GAPDH (ab8245, Abcam Inc.;
dilution 1:10,000). The following secondary antibodies were
used: goat anti-rabbit IgG (ab97200, Abcam Inc.; dilution
1:5,000), goat anti-mouse IgG (130043, KPL, Gaithersburg,
USA; dilution 1:10,000). As a positive control for western
blot analyses, active human SDF1 beta full length protein
(abcam) was used.Histological and immunohistochemical staining
Histological and immunohistochemical staining analyses
were performed as follows: cross sections (3 mm thick) were
cut from AAA and control tissue blocks, mounted on slides
treated with 0.1% poly-L-lysine solution (Sigma-Aldrich, St.
Louis, MO, USA) for better adhesion, and dried for 1e
2 hours at 56 C before staining. Hematoxylin and eosin
(HE) and Elastica van Gieson (EvG) staining were performed
to characterize the morphology of the aortic wall. For
immunohistochemical staining, the sections were de-
parafﬁnized, rehydrated, placed in 10 mM citrate buffer
(pH 6.0), and treated in a pressure cooker for 7 minutes. For
CXCR4 and CXCL12, a target retrieval buffer with pH 9.0
(S2367, Dako REALTM, Inc) was used and sections were
treated for 20 minutes in a microwave, pre-incubated with
0.3% hydrogen peroxide (H2O2) for 15 minutes at room
temperature to block endogenous peroxidase activity.
Subsequently, the sections were pre-treated with 1% bovine
serum albumin in background reducing diluents (S2022,
Dako REAL, Inc) and then incubated with the appropriateantibodies: anti-CXCR4 antibody (ab124824, Abcam Inc.;
dilution 1:300), anti-SDF-1a (CXCL12) antibody (ab9797,
Abcam Inc.; dilution 1:500/1,000), T lymphocytes (anti-CD3,
MRQ-39, Cell Marque; dilution 1:500), B lymphocytes (anti-
CD20, M0755, clone L26, Dako; dilution 1:500), macro-
phages/monocytes (anti-CD68, M0814, Dako; dilution
1:2,000), and plasma cells (anti-VS38c, M7077, Dako, dilu-
tion 1:1,000). Thereafter, the sections were incubated with
biotinylated secondary antibody for 25 minutes, followed by
peroxidase conjugated streptavidin for another 25 minutes.
Finally the sections were incubated in 3,3’-dia-
minobenzidine (DAB) chromogen for 3e5 minutes, coun-
terstained with Mayer’s hematoxylin, and mounted.
Exclusion of the primary antibody during immunostaining
was used as a negative control, while tonsil sections served
as a positive control.Statistical evaluation
All statistical analyses were performed using SPSS for
Windows version 20.0 (SPSS Inc., Chicago, IL, USA). To
compare values of continuous variables, a non-parametric
ManneWhitney U test was used. Correlations between
continuous variables were quantiﬁed using Spearman’s rank
correlation coefﬁcient. All statistical tests were two sided. A
p value < .05 was considered signiﬁcant.
RESULTS
Expression of CXCR4/CXCL12 at mRNA level
Using quantitative real time RT-PCR, the mRNA levels of the
chemokine receptor CXCR4 and its ligand CXCL12, as well as
the inﬂammatory markers for T and B lymphocytes and
macrophages were detected in the AAA wall excised from
the anterior or lateral sac at the maximum dilatation site as
well as in the control tissue samples (Fig. 1). Following
standardization to the expression of GAPDH, AAA samples
showed signiﬁcantly increased mRNA expression levels for
CXCR4 compared with control aorta by 9.6 times
(p ¼ .0004). The expression of CXCL12 was increased 4.6
fold (p < .0001), CD45 6.3 fold (p < .0001), CD3 10.3 fold
(p ¼ .014), and MSR1 16.6 fold (p < .001) in comparison
with the control subjects.
Furthermore, because the study groups (AAA vs. control
aorta) were not age matched, correlation analysis between
age and the expression of CXCR4 and CXCL12 in the AAA
patients and in the control group was performed, calcu-
lating the Spearman rank correlation coefﬁcient. No signif-
icant relationships were observed (AAA group: r ¼ 0.38;
p ¼ .849 for CXCR4 and r ¼ .104; p ¼ .570 for CXCL12;
control group: r ¼ .447; p ¼ .168 for CXCR4, and r ¼ .451;
p ¼ .190 for CXCL12).Relationship between the gene expression of CXCR4,
CXCL12, and selected inﬂammatory markers
As the chemokine receptor CXCR4 is known to be involved
in lymphocyte activation, differentiation, and trafﬁcking at
the site of inﬂammation, it was also determined whether
Figure 1. Expression of CXCR4, CXCL12, and inﬂammatory markers:MSR1, CD45, CD3 at the mRNA level in the AAA tissue samples (n ¼ 32)
compared with healthy control tissues (n ¼ 12) analyzed by quantitative real time polymerase chain reaction and SYBR green ﬂuorescence
dye; the expression levels were standardized to GAPDH. The ManneWhitney U test was used. AAA ¼ abdominal aortic aneurysm; CD,
cluster of differentiation; MSR1, macrophages scavenger receptor 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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ﬂammatory cells in the AAA wall (Table 2). Positive corre-
lations were observed between the expression of CXCR4
and the expression of CXCL12, MSR1, CD45, and CD3
(p < .001, p ¼ .002, p < .001 and p ¼ .002, respectively).
Furthermore, CXCL12 was signiﬁcantly correlated with the
inﬂammatory markers MSR1, CD45, and CD3 as well
(p < .001, p < .001, and p ¼ .001, respectively).
Expression of CXCR4/CXCL12 at protein level
Following expression analysis at the mRNA level, the
expression of CXCR4 and CXCL12 in the AAA tissue samplesTable 2. Correlation between the expression of CXCR4 and CXCL12
at mRNA level and inﬂammatory markers analyzed within the AAA
wall. Correlations were calculated using the Spearman rank
correlation coefﬁcient (r).
CXCR4 CXCL12 MSR1 CD45 CD3
CXCR4
CXCL12 0.761**
MSR1 0.532** 0.712**
CD45 0.746** 0.822** 0.663**
CD3 0.535** 0.549** 0.414* 0.581**
AAA ¼ abdominal aortic aneurysm.
*p < .05; **p < .01.was determined at the protein level using western blot
analysis (Fig. 2). The expression of CXCR4 was found in AAA
and in the control group at the expected protein size
(43 kDa). In contrast, the expression of CXCL12 (11 kDa) at
protein level could not be detected. An example of the
protein bands is shown in Fig. 2. The protein level of CXCR4
in AAA tissue samples in comparison with the control
subjects was increased 3.2 fold (p < .0001). In contrast to
CXCR4, the western blot analysis did not lead to any
detection of protein bands for CXCL12, with the exception
of the control protein (Fig. 2).Cellular localization of CXCR4 in AAA and controls
determined by immunohistochemistry
Histological and immunohistochemical analyses were per-
formed for associating the expression of CXCR4 and CXCL12
to the different cell types within the AAA wall. The most
abundant cells detected in AAA samples, as already shown
in previous work,4 were smooth muscle cells (SMCs) and
inﬂammatory cells such as lymphocytes and macrophages.
The immunohistochemical analyses of the chemokine re-
ceptor CXCR4 and its ligand CXCL12 are shown in Fig. 3.
CXCR4 staining was positive for B and T lymphocytes, as
well as for macrophages, indicating that these cells exhibi-
ted the highest expression of CXCR4. Interestingly,
Figure 2. Expression of CXCR4 and CXCL12 at the protein level in
AAA tissue samples (n ¼ 32) compared with healthy control tissues
(Ctrl, n ¼ 12) analyzed by western blot. Recombinant CXCL12
protein was used as positive control (Pos. ctrl, 0.1 mg/lane).
CXCL12 protein was not detected either in AAA or in healthy aorta.
The intensities of the bands following blotting and
chemiluminescence detection were standardized to GAPDH.
AAA ¼ abdominal aortic aneurysm; GAPDH ¼ glyceraldehyde-3-
phosphate dehydrogenase. The ManneWhitney U test was used.
CXCR4 in abdominal aortic aneurysm 749neovessels were also partially positive for the staining (data
not shown). With regard to CXCL12, immunohistochemical
analysis only revealed positive staining for plasma cells
(Fig. 4). All other cells in the AAA wall and in control aorta
were negative for CXCL12.DISCUSSION
In this study it has been demonstrated that the expression
of CXCR4 and its ligand CXCL12 is signiﬁcantly upregulated
in human AAA compared with non-aneurysmal aortic tissue.
Furthermore, CXCR4 is mainly localized in inﬂammatory
cells, in particular in B and T lymphocytes, as well as in
macrophages.
AAA is a complex degenerative disease, characterized by
the accumulation of inﬁltrating cells such as macrophages
and lymphocytes.6,28e37 The inﬂammatory processes
within the AAA wall are initiated by multiple factors,
including various pro-inﬂammatory cytokines, chemokines,
and their receptors. A special focus has recently been
devoted to the chemokine receptor CXCR4 and intensively
investigated in various tumors, cancer,21,22 and brain dis-
orders,23,24 as well as in atherosclerosis,28 which is also
known to be associated with AAA progression. CXCR4 has
been shown to be critical for adhesion and/or migration by
mediating trafﬁcking and activation of lymphocytes,suggesting the involvement of CXCR4 in tumor progres-
sion, invasion, and metastasis.19e23 Interestingly, only a
few groups have so far analyzed the chemokine receptor
CXCR4 and its ligand in human AAA in order to examine
their role in lymphoid recruitment25 and to evaluate the
expression of CXCL12/CXCR4 in the aneurysmal aortic wall
and during AAA progression in a mouse model.26 In this
study the focus was on the expression of CXCR4 and its
ligand CXCL12 in the aortic wall of AAA patients and non-
aneurysmal tissue subjects at the protein and mRNA levels
and on the association of their expression in individual
cells within the AAA wall.
First, to evaluate the presence of CXCR4 and CXCL12 in
AAA tissue samples, the mRNA level was determined. The
gene expression of CXCR4 and CXCL12 was detected in
AAA samples as well as in non-aneurysmal aortas.
Nevertheless, the expression of CXCR4 showed a signiﬁ-
cant increase in AAA tissues samples of 9.6-fold, and 4.6-
fold for CXCL12, compared with non-aneurysmal aorta.
These results were in accordance with the previous pub-
lished study from Lenk et al.,29 who used Affymetrix and
Illumina arrays on 10 AAA tissues samples and 10 control
aortae. Lenk et al.29 observed signiﬁcantly increased
expression of CXCR4 in AAA attributed to leukocytes.
Furthermore, another study analyzed 15 AAA and 15
control aortic tissue samples using a custom designed AAA
chip and observed 38 differentially expressed genes be-
tween AAA and control samples. One of these genes was
CXCR4 with 6.9-fold increase in AAA wall.30 Both studies
were carried out with control samples obtained from age,
sex, and ethnicity matched individuals and all were from
the infrarenal region of the aorta. Consequently, upregu-
lation of CXCR4 expression in AAA versus healthy aorta
was conﬁrmed, even if the control group was not
matched. It is however of note that a correlation analysis
to ﬁgure out any relationship between age and expression
of either CXCR4 or CXL12 in the tissue samples was per-
formed. No correlation was observed. Therefore, in
accordance with the other already published studies, it
was assumed that age did not affect the comparison be-
tween the study groups. Because both factors are asso-
ciated with the activation of inﬂammatory cells, their gene
expression was correlated with the expression of the
following inﬂammatory cells markers: MSR1, CD45, and
CD3. Interestingly, signiﬁcantly positive correlations were
observed between the gene expression of CXCR4, CXCL12,
and all these inﬂammatory markers (Table 2), indicating
that gene expression of CXCR4 and CXCL12 is concomitant
with inﬂammatory cells within the AAA wall. The results
were in agreement with previous studies that showed that
CXCR4 and CXCL12 are upregulated in human25 and in
mouse AAAs.26 Remarkably, CXCR4 transcription was also
detected in the healthy aorta, although it was associated
with CXCR4 expression mainly in inﬂammatory cells. This
discrepancy might be explained by using elderly in-
dividuals as controls, who had already slightly enlarged
intima containing monocytes and by the presence of in-
ﬂammatory cells in the adventitia.
Figure 3. (A) Immunohistochemical analyses of CXCR4 in AAA tissue samples and in healthy tissues. (B) Selective immunohistochemical
staining of CXCR4, CD68, CD3, and CD20 within the abdominal aortic aneurysm tissues samples. Positive cells are brown and counter-
stained with hematoxylin and eosin, showing cell nucleus in blue. Scale bars are 200 mm. The inserts are high power images of the selected
regions. Scale bars are 10 mm.
Figure 4. Immunohistochemical staining of CXCL12 and VS38c (plasma cells) within the AAA tissue samples. Positive cells are brown, the
cells are counterstained with hematoxylin and eosin, showing the cell nucleus in blue. Scale bars are 200 mm. The inserts are high power
images of the selected regions. Scale bars are 10 mm.
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expression of CXCR4 also at protein level. Interestingly, even
if no expression of CXCL12 at the mRNA level was found, no
protein could be detected. These results are in discordance
with the ﬁndings of Ocaña,25 who detected CXCL12 in
adventitia of the AAA wall. This apparent disagreement
could be explained by differences in the methodology.
Ocaña et al. analyzed the expression of CXCL12 by immu-
nohistochemical staining25; in contrast, in this study evalu-
ation was by expression via western blot, which is often less
sensitive than immunohistochemistry. Using recombinant
CXCL12 protein, the limit of detection was 0.1 mg. Conse-
quently, if the protein concentration was lower, it could not
be detected in the western blot analysis. Since the CXCL12
positive cells in the study of Ocaña et al. expressed neither
CD45 marker of inﬂammatory cells nor smooth muscle actin
or CD34, the precise source of CXCL12 could not be iden-
tiﬁed.25 This work focused on inﬂammatory cells within the
AAA, which was negative for CXCL12, as in the study of
Ocaña et al.25 However, CXCL12 positive cells associated
only with plasma cells were detected. This can be inter-
preted such that these cells might be activated by an
autoimmune response in the AAA wall as result of chronic
inﬂammation.38 Whether plasma cells are capable of
expressing CXCL12 has to be further elucidated. Further-
more, the lack of detection of CXCL12 at the protein level
could also be for the following reasons. First, protein and
mRNA expression levels are known to be independent of
each other.39 Second, the half life of proteins is often
different from that of the corresponding mRNA.40 In
accordance, CXCR4 as a transmembrane receptor is a stable
protein. In contrast, the half-life of CXCL12 has been
described as rather short.41 Thus, the instability of CXCL12
might be another reason that this ligand could not be
detected at the protein level.
Finally, to determine the cells within the AAA wall that
express CXCR4 or CXCL12, consecutive immunohistological
staining was performed for B and T lymphocytes and
macrophages. These cells have already been classiﬁed as
important sources of inﬂammatory processes, which
invade the aortic vessel wall during the pathogenesis of
AAA.4,6 The results indicated that B and T lymphocytes as
well as macrophages express CXCR4. Furthermore, simi-
larly to CXCL12, CXCR4 was detected in plasma cells also.
These cells differentiate from B cells and produce anti-
bodies from the precursor B cell. The presence of plasma
cells and B lymphocytes in the aneurysm,4 together with
the expression of CXCR4/CXCL12, further supports the
assumption that an autoimmune reaction might be also
involved in AAA disease progression. Additionally, CXCR4
and CXCL12 positive cells were not detected in healthy
aorta tissues. These ﬁndings conﬁrm once again the critical
role of inﬂammation, which participates in a negative
remodeling of extracellular matrix throughout the arterial
wall leading to the vessel wall instability, AAA progression,
and ﬁnally to rupture.4,33e37 Furthermore, these results
are in accordance with a recent study demonstrating that
the CXCL12/CXCR4 pathway in the development andprogression of AAAs is triggered through the accumulation
of macrophages within the diseased aortic wall.26 More-
over, Bot et al.28 recently described that blockade of
CXCR4/SDF-1a on leukocytes induces atherosclerotic pla-
que progression in mice. Taken together, these results
emphasize that the expression and appearance of CXCR4
may correspond with the AAA progression and might be a
potential target for detection of inﬂammatory activity in
AAA patients.
Study limitation
The non-aneurysmal control group used in this study was
not age matched with the AAA study group, which could be
a source of potential bias. It is extremely difﬁcult to obtain
healthy aortic samples, thus the available tissue material
had to be used. It is also of note that no information was
available with regard to medical history or medication of
the healthy donors, such as hypertension, CKD, or diabetes
mellitus, or the administration of statins, which could also
inﬂuence the expression of the studied inﬂammatory
markers. Furthermore, the immunohistochemistry results
strongly depend upon the antibody used. Several antibodies
were tested for both CXCR4 and CXCL12 to receive optimal
staining outcome; nevertheless, especially with regard to
CXCL12, the negative results might also be due to the
insufﬁcient sensitivity of the antibodies used in the study.
Additionally, it is important to mention that the results
provide only an association between the expression of
CXCR4 and the inﬂammatory markers rather than the
mechanism of biochemical cascade, which can be partially
caused by global increase in gene expression in the in-
ﬂammatory cells. Further functional studies are therefore
necessary to elucidate the exact role of CXCR4/CXCL12 in
AAA.
In summary, in contrast to other studies that analyzed
CXCR4 separately either at mRNA level using array chips or
by immunohistochemistry, this study focused on all three
techniques: PCR, western blotting, and immunohistochem-
istry. The results demonstrate that CXCR4 is abundantly
expressed in AAA tissue samples at both the RNA and the
protein level compared with non-aneurysmal tissues.
Furthermore, CXCR4 is particularly co-localized with in-
ﬂammatory cells in the AAA wall. Thus, CXCR4 may serve as
a potential target to detect non-invasively inﬂammatory
activity in the diseased aortic wall. Further studies are
necessary to validate the role of CXCR4 in the inﬂammatory
proteolytic processes within the human AAA wall.
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